VYNE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

200.00K

+138.1%

-0.180

-35.71%

200.00K

-0.99%

-0.180

-10%

200.00K

+189.86%

-0.180

+38.46%

Estimates Revision

The market is revising No Change the revenue expectations for VYNE Therapeutics Inc. (VYNE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 36.09%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+32.28%

In Past 3 Month

Stock Price

Go Up

+36.09%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast VYNE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VYNE is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.00

Averages

2.00

High

2.00

Current: 0.000

Low

2.00

Averages

2.00

High

2.00

H.C. Wainwright

Joseph Pantginis

Buy

Neutral

downgrade

2025-07-30

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

2025-07-30

downgrade

Buy

Neutral

Reason

H.C. Wainwright analyst Joseph Pantginis downgraded VYNE Therapeutics to Neutral from Buy.

H.C. Wainwright

Buy

Neutral

downgrade

$4.50

2025-07-30

Reason

H.C. Wainwright

Price Target

$4.50

2025-07-30

downgrade

Buy

Neutral

Reason

H.C. Wainwright downgraded VYNE Therapeutics to Neutral from Buy and removed the firm's prior $4.50 price target after the company's Phase 2b trial assessing repibresib in nonsegmental vitiligo did not achieve its primary endpoint and also missed the secondary endpoint. The Phase 2b result is "a surprise to us" that "puts the company in a precarious position," the analyst tells investors. While stating that the company ends this trial in "a relatively stable financial position," the firm says the current risk profile "pushes us to the sidelines," pending visibility on the path forward for repibresib, additional VYN202 data and/or the acquisition of new assets to pursue.

BTIG

Julien Harrison

Buy -> Neutral

downgrade

2025-07-30

Reason

BTIG

Julien Harrison

Price Target

2025-07-30

downgrade

Buy -> Neutral

Reason

BTIG analyst Julien Harrison downgraded VYNE Therapeutics to Neutral from Buy with no price target after the company's Phase 2b trial assessing repibresib in nonsegmental vitiligo did not achieve its primary endpoint and also missed the secondary endpoint. The full data set will be further analyzed to inform results and strategic next steps, while the management intends to seek a development and commercialization partner for repibresib and plans to provide an update on repibresib and VYN202, which is currently on partial clinical hold by the FDA, plans in the coming weeks, the analyst tells investors in a research note.

H.C. Wainwright

Neutral

downgrade

2025-04-25

Reason

H.C. Wainwright

Price Target

2025-04-25

downgrade

Neutral

Reason

H.C. Wainwright lowered the firm's price target on VYNE Therapeutics to $4.50 from $5.75 and keeps a Neutral rating on the shares after the FDA placed a clinical hold on the company;s Phase 1b study evaluating VYN202 in moderate-to-severe plaque psoriasis. The firm finds it important that there have been no serious adverse events observed in subjects that have been enrolled in the Phase 1b study to date. It should also be underscored that this clinical hold only applies to the VYV202 program, the analyst tells investors in a research note. VYNE's ongoing Phase 2b trial assessing repibresib gel in nonsegmental vitiligo continues without interruption, contends H.C. Wainwright.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$5.75

2025-03-06

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$5.75

2025-03-06

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$5.75

2025-01-14

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$5.75

2025-01-14

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Vyne Therapeutics Inc (VYNE.O) is -0.75, compared to its 5-year average forward P/E of -1.82. For a more detailed relative valuation and DCF analysis to assess Vyne Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.82

Current PE

-0.75

Overvalued PE

-0.48

Undervalued PE

-3.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.15

Current EV/EBITDA

0.27

Overvalued EV/EBITDA

1.38

Undervalued EV/EBITDA

-1.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

57.40

Current PS

24.91

Overvalued PS

104.72

Undervalued PS

10.07

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

VYNE News & Events

Events Timeline

No data

News

8.5

2025-12-20Globenewswire

Amicus Therapeutics to Sell to BioMarin for $14.50 per Share

7.0

2025-12-19PRnewswire

Ademi Firm Investigates VYNE for Potential Fiduciary Breaches in Yarrow Transaction

7.0

2025-12-17PRnewswire

Monteverde & Associates Investigates VYNE Therapeutics Merger with Yarrow Bioscience

People Also Watch

Frequently Asked Questions

What is Vyne Therapeutics Inc (VYNE) stock price today?

The current price of VYNE is 0.5619 USD — it has decreased -1.23 % in the last trading day.

What is Vyne Therapeutics Inc (VYNE)'s business?

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

What is the price predicton of VYNE Stock?

What is Vyne Therapeutics Inc (VYNE)'s revenue for the last quarter?

Vyne Therapeutics Inc revenue for the last quarter amounts to 169.00K USD, increased 39.67 % YoY.

What is Vyne Therapeutics Inc (VYNE)'s earnings per share (EPS) for the last quarter?

Vyne Therapeutics Inc. EPS for the last quarter amounts to -0.17 USD, decreased -41.38 % YoY.

What changes have occurred in the market's expectations for Vyne Therapeutics Inc (VYNE)'s fundamentals?

How many employees does Vyne Therapeutics Inc (VYNE). have?

Vyne Therapeutics Inc (VYNE) has 13 emplpoyees as of January 09 2026.

What is Vyne Therapeutics Inc (VYNE) market cap?

Today VYNE has the market capitalization of 18.94M USD.